Abstract

By providing structures to learn about the mechanisms of disease pathogenesis that should result in new therapies or reveal medication sensitivities, induced pluripotent stem cell (iPSC) technology is creating exciting new opportunities for cardiovascular research. The practical relevance of iPSC-derived cardiomyocytes in drug development and toxicity testing is explored in this study, with a focus on the advancements that have already been accomplished in this area. Additionally, it highlights the crucial steps that must be accomplished before this research may be widely applied in drug discovery and toxicological evaluations.